Development asset linked to CITIUS ONCOLOGY in public FDA and regional records.
pharma · Hemorrhoids · Persistent or Recurrent Cutaneous T-Cell Lymphoma · CTOR
CITIUS ONCOLOGY
CITIUS ONCOLOGY, INC.
CITIUS ONCOLOGY drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cranford, USA HQ
2024 Founded
5 Employees
Public company Type
CTOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cranford, USA
- Founded
- 2024
- Employees
- 5
- Programs
- 3
- Drugs
- 8
- Patents
- 0
CITIUS ONCOLOGY pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CITIUS ONCOLOGY drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to CITIUS ONCOLOGY in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
lidocaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to CITIUS ONCOLOGY in public FDA and regional records.